U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Tue Apr 01 16:22:40 GMT 2025
Edited
by admin
on Tue Apr 01 16:22:40 GMT 2025
Protein Type MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type FAB
Sequence Origin HUMANIZED
Sequence Type COMPLETE
Record UNII
T3V24FDA87
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
rivabazumab pegol [INN]
Preferred Name English
RIVABAZUMAB PEGOL
INN   WHO-DD  
INN  
Official Name English
Rivabazumab pegol [WHO-DD]
Common Name English
IMMUNOGLOBULIN FAB' G1-KAPPA PEGYLATED, ANTI-PSEUDOMONAS AERUGINOSA TYPE III SECRETION SYSTEM (TTSS)PCRV PROTEIN, PEGYLATED HUMANIZED MONOCLONAL ANTIBODY
Common Name English
KB001-A
Common Name English
KB001-A (AN ANTI-PCRV PEGYLATED MONOCLONAL ANTIBODY FRAGMENT TO THE TYPE III SECRETION SYSTEM OF PSEUDOMONAS AERUGINOSA)
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C20401
Created by admin on Tue Apr 01 16:22:40 GMT 2025 , Edited by admin on Tue Apr 01 16:22:40 GMT 2025
NCI_THESAURUS C52588
Created by admin on Tue Apr 01 16:22:40 GMT 2025 , Edited by admin on Tue Apr 01 16:22:40 GMT 2025
Code System Code Type Description
FDA UNII
T3V24FDA87
Created by admin on Tue Apr 01 16:22:40 GMT 2025 , Edited by admin on Tue Apr 01 16:22:40 GMT 2025
PRIMARY
INN
10144
Created by admin on Tue Apr 01 16:22:40 GMT 2025 , Edited by admin on Tue Apr 01 16:22:40 GMT 2025
PRIMARY
CAS
1613506-32-3
Created by admin on Tue Apr 01 16:22:40 GMT 2025 , Edited by admin on Tue Apr 01 16:22:40 GMT 2025
PRIMARY
NCI_THESAURUS
C152236
Created by admin on Tue Apr 01 16:22:40 GMT 2025 , Edited by admin on Tue Apr 01 16:22:40 GMT 2025
PRIMARY
SMS_ID
300000024696
Created by admin on Tue Apr 01 16:22:40 GMT 2025 , Edited by admin on Tue Apr 01 16:22:40 GMT 2025
PRIMARY
From To
1_22 1_96
1_151 1_207
2_23 2_88
2_134 2_194
Related Record Type Details
TARGET ORGANISM->INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID SUBSTITUTION [1_233] [1_236] C S-(1-(3-((3-HYDROXYPROPYL)AMINO)-3-OXOPROPYL)-2,5-DIOXO-3-PYRROLIDINYL)CYSTEINYL METHOXY PEG-30 ETHER 8O5A0CG609
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL